natgillin/translations-raw huggingface dataset:
Lejlighedsvist kan en infektion i den indre del af øjet, smerter eller rødme (inflammation), løsning eller rift i et af lagene bagest i øjet (nethindeløsning eller –rift og løsning eller rift i nethindepigmentepitel) eller uklarhed af linsen (katarakt) forekomme efter behandling med Lucentis.
Occasionally, an infection in the internal portion of the eye, pain or redness (inflammation), detachment or tear of one of the layers in the back of the eye (retinal detachment or tear and retinal pigment epithelial detachment or tear), or clouding of the lens (cataract) may occur after Lucentis treatment.
lejlighedsvist sammen med
diabetes occasionally associated with
lejlighedsvist sammen med
occasionally associated with
Lek Pharmaceuticals d.d., Verovškova 57, 1526 Ljubljana, Slovenien
Lek Pharmaceuticals d.d., Verovškova 57, 1526 Ljubljana, Slovenia
LEMMT (gennemsnit SEM, ) (Manuel muskeltest for underekstremiteter)
LEMMT (mean, sem) (Lower Extremity Manual Muscle Test)
LEMTRADA 12 mg (N = 426)
LEMTRADA 12 mg (N=426)
LEMTRADA indeholder det aktive stof alemtuzumab, der anvendes til behandling af den type af multipel sklerose (MS) hos voksne, der kaldes recidiverende-remitterende MS (RRMS).
LEMTRADA contains the active substance alemtuzumab, which is used to treat a form of multiple sclerosis (MS) in adults, called relapsing remitting MS (RRMS).
LEMTRADA indeholder ingen konserveringsmidler, og der skal derfor tages forholdsregler til at sikre sterilitet.
LEMTRADA contains no antimicrobial preservatives and, therefore, care should be taken to ensure the sterility of the prepared solution.
LEMTRADA kan give anledning til forskellige typer af skjoldbruskkirtel-lidelser herunder:
LEMTRADA may cause different types of thyroid disorders, including:
LEMTRADA kun gives, hvis den potentielle virkning opvejer de potentielle risici.
LEMTRADA should be administered if the potential benefit justifies the potential risks.
LEMTRADA tjekliste til den ordinerende læge
LEMTRADA Prescriber’s Check-list
LEMTRADA træningsmodul
LEMTRADA Training Module
LEMTRADA udtømmer cirkulerende T- og B-lymfocytter efter hvert behandlingsforløb med de lavest observerede værdier 1 måned efter et behandlingsforløb (det tidligste postbehandlingstidspunkt i fase-3- studier).
LEMTRADA depletes circulating T and B lymphocytes after each treatment course with the lowest observed values occurring 1 month after a course of treatment (the earliest post-treatment time point in phase 3 studies).
LEMTRADA vejledning til sundhedspersonale
LEMTRADA Health Care Professional Guide
LEMTRADA-behandling skal initieres og superviseres af en neurolog med erfaring i behandling af patienter med MS.
LEMTRADA treatment should be initiated and supervised by a neurologist experienced in the treatment of patients with MS.
LEMTRADA-infusion
LEMTRADA infusion
LEMTRADA-infusionsvæske administreres via intravenøs administration over cirka 4 timer.
Administer LEMTRADA infusion solution via intravenous administration over approximately 4 hours.
LEMTRADAs farmakokinetik er ikke blevet undersøgt hos patienter i alderen 55 år og derover.
The pharmacokinetics of LEMTRADA has not been studied in patients aged 55 years and older.
LEMTRADAs farmakokinetiske egenskaber blev evalueret hos i alt 216 patienter med RRMS, der fik intravenøse infusion af enten 12 mg/dag eller 24 mg/dag på 5 på hinanden følgende dage og derefter i 3 på hinanden følgende dage 12 måneder efter det første behandlingsforløb.
The pharmacokinetics of LEMTRADA were evaluated in a total of 216 patients with RRMS who received intravenous infusions of either 12 mg/day or 24 mg/day for 5 consecutive days, followed by 3 consecutive days 12 months following the initial treatment course.
LEMTRADAs sikkerhed og virkning blev evalueret i 3 randomiserede, rater-blindede, aktiv-komperator kliniske forsøg med RRMS-patienter.
The safety and efficacy of LEMTRADA were evaluated in 3 randomised, rater-blinded, active-comparator clinical trials in patients with RRMS.
Lenalidomid (25 mg) oralt
Lenalidomide (25 mg) Oral
Lenalidomid 25 mg blev indtaget oralt en gang dagligt i de første 3 uger af hver cyklus.
Lenalidomide 25 mg was taken orally once daily for the first 3 weeks of each cycle.
Lenalidomid binder direkte til cereblon, en komponent af et cullin-ring E3 ubiquitinligase enzymkompleks, der omfatter deoxyribonukleinsyre (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4) og regulator for cullin 1 (Roc1).
Lenalidomide binds directly to cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex that includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and regulator of cullins 1 (Roc1).
Lenalidomid bør ikke anvendes til behandling af patienter med stor tumorbyrde, hvis der er alternative behandlingsmuligheder.
Lenalidomide is not recommended for the treatment of patients with high tumour burden if alternative treatment options are available.
Lenalidomid er blevet evalueret i to fase III-studier af nydiagnosticeret myelomatose og i to fase III- studier af recidiverende refraktær myelomatose, som beskrevet nedenfor.
Lenalidomide has been evaluated in two phase III studies in newly diagnosed multiple myeloma and two phase III studies in relapsed refractory multiple myeloma as described below.
Lenalidomid er forbundet med en højere forekomst af grad 3 eller 4 trombocytopeni (37 % hos lenalidomidbehandlede patienter, sammenlignet med 1,5 % hos patienter på placebo i fase III-studiet).
Lenalidomide is associated with a higher incidence of grade 3 or 4 thrombocytopenia (37% in lenalidomide-treated patients compared with 1.5% in patients on placebo in the Phase III study).
Lenalidomid findes i blod og sæd hos patienter, der får lægemidlet.
Lenalidomide is present in the blood and sperm of patients receiving the medicine.
Lenalidomid forventes at være skadeligt for det ufødte barn.
Lenalidomide is expected to be harmful for an unborn baby.
Lenalidomid forventes at være skadeligt for det ufødte barn.
Lenalidomide is expected to be harmful to the unborn child.
Lenalidomid forventes at være skadeligt for et ufødt barn.
Lenalidomide is expected to be harmful to an unborn child.
Lenalidomid i kombination med dexamethason hos patienter, der ikke er kandidater til stamcelletransplantation
Lenalidomide in combination with dexamethasone in patients who are not candidates for stem cell transplantation
Lenalidomid i kombination med melphalan og prednison efterfulgt af vedligeholdelsesbehandling med ét stof hos patienter, der ikke er egnede til transplantation
Lenalidomide in combination with melphalan and prednisone followed by maintenance monotherapy in patients who are not eligible for transplant
Lenalidomid i kombination med melphalan og prednison, efterfulgt af vedligeholdelsesbehandling med ét stof hos patienter, der ikke er egnede til transplantation
Lenalidomide in combination with melphalan and prednisone followed by maintenance monotherapy in patients who are not eligible for transplant
Lenalidomid kan fortsættes hos patienter med grad 1 eller 2 tumor-flare-reaktion (TFR) uden behandlingsafbrydelse eller dosisjustering, i henhold til lægens skøn.
Lenalidomide may be continued in patients with Grade 1 or 2 tumour flare reaction (TFR) without interruption or modification, at the physician’s discretion.
Lenalidomid regnes med at være skadeligt for det ufødte barn.
Lenalidomide is expected to be harmful to the unborn child.
Lenalidomid udskilles især igennem nyrerne.
Lenalidomide is substantially excreted by the kidney.
Lenalidomid virker på forskellige måder: Det blokerer for abnorme cellers vækst, forhindrer blodkarvækst i svulsterne og stimulerer desuden forskellige specialiserede celler i immunsystemet til at angribe de abnorme celler.
Lenalidomide works in a number of different ways: it blocks the development of abnormal cells, prevents the growth of blood vessels within tumours and also stimulates some of the specialised cells of the immune system to attack the abnormal cells.
Lenalidomid-behandlingen må ikke startes, hvis det absolutte neutrofiltal (absolute neutrophil count, ANC) er < 1,5 x 109/l, og/eller trombocyttallet er < 75 x 109/l.
Lenalidomide treatment must not be started if the Absolute Neutrophil Count (ANC) is < 1.5 x 109/L, and/or platelet counts are < 75 x 109/L.
Lenalidomid-behandlingen må ikke startes, hvis det absolutte neutrofiltal (absolute neutrophil counts, ANC) er < 1,0 x 109/l, og/eller trombocyttallet er < 50 x 109/l.
Lenalidomide treatment must not be started if the Absolute Neutrophil Count (ANC) is < 1.0 x 109/L, and/or platelet counts are < 50 x 109/L.
Lenalidomid/ dexamethason N = 325
Lenalidomide/ Dexamethasone N = 325
Lenalidomidarm
37.6 [24.0, 52.6]
Lenalidomids farmakokinetik blev undersøgt hos personer med nedsat nyrefunktion, der skyldes ikke- maligne sygdomme.
The pharmacokinetics of lenalidomide was studied in subjects with renal impairment due to nonmalignant conditions.
Lenalidomids primære, dosisbegrænsende toksiciteter er neutropeni og trombocytopeni.
The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia.
Lenalidomids sikkerhed og virkning blev evalueret hos patienter med transfusionsafhængig anæmi, der skyldes lav- eller intermediær 1-risiko myelodysplastisk syndrom med en deletion 5q cytogenisk anomali, med eller uden yderligere cytogeniske anomalier i to primære studier: et multicenter, randomiseret, dobbeltblindt, placebokontrolleret 3-arms fase III-studie af to doser af oral lenalidomid (10 mg og 5 mg) versus placebo (MDS-004) og et multicenter, enkeltarms, open-label fase II-studie af lenalidomid (10 mg) (MDS-003).
The efficacy and safety of lenalidomide were evaluated in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities, in two main studies: a Phase III, multicentre, randomised, double-blind, placebo-controlled, 3-arm study of two doses of oral lenalidomide (10 mg and 5 mg) versus placebo (MDS-004); and a Phase II, a multicentre, single-arm, open-label study of lenalidomide (10 mg) (MDS-003).
Lenalidomids sikkerhed og virkning blev vurderet i et fase III randomiseret, dobbeltblindet multicenterstudie med tre arme (MM-015) hos patienter i alderen 65 år eller ældre, der havde serumkreatinin < 2,5 mg/dl.
The safety and efficacy of lenalidomide was assessed in a Phase III multicenter, randomized double blind 3 arm study (MM-015) of patients who were 65 years or older and had a serum creatinine < 2.5 mg/dL.
Lenalidomids virkning og sikkerhed blev evalueret hos patienter med mantelcellelymfom i et randomiseret, åbent fase II-multicenterstudie versus investigators valg af enkeltstof hos patienter, som var refraktære over for deres sidste behandlingsregime, eller som havde recidiveret en til tre gange (studie MCL-002).
The efficacy and safety of lenalidomide were evaluated in patients with mantle cell lymphoma in a phase II, multicenter, randomized open-label study versus single agent of investigator’s choice in patients who were refractory to their last regimen or had relapsed one to three times (Study MCL-002).
Lennox-Gastaut syndrom er en af de mest alvorlige former for epilepsi hos børn.
Lennox-Gastaut syndrome is one of the most severe forms of epilepsy in children.
Lenvatinib bør genoptages med en reduceret dosis, når QTc-forlængelsen har fortaget sig til < 480 ms eller baseline.
Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to < 480 ms or baseline.
Lenvatinib bør genoptages med en reduceret dosis, når QTc-forlængelsen har fortaget sig til < 480 ms eller til baseline-niveau.
Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to < 480 ms or baseline.
Lenvatinib bør pauseres i tilfælde af forlængelse af QT-intervallet til over 500 ms.
Lenvatinib should be withheld in the event of development of QT interval prolongation greater than 500 ms.
Lenvatinib er en receptortyrosinkinase (RTK)-hæmmer, der selektivt hæmmer kinaseaktiviteten af vaskulær endotel-vækstfaktor (VEGF)-receptorerne VEGFR1 (FLT1), VEGFR2 (KDR) og VEGFR3 (FLT4) foruden andre proangiogene og onkogene reaktionsvejsrelaterede RTK'er, herunder fibroblastvækstfaktor (FGF)-receptorerne FGFR1, 2, 3 og 4, trombocytderiveret vækstfaktor (PDGF)- receptor PDGFRα, KIT og RET.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.
Lenvatinib er en receptortyrosinkinase (RTK)-hæmmer, der selektivt hæmmer kinaseaktiviteterne af vaskulærendotelvækstfaktor (VEGF)-receptorer VEGFR1 (FLT1), VEGFR2 (KDR) og VEGFR3 (FLT4) foruden andre proangiogene og onkogene reaktionsvejsrelaterede RTK'er, herunder fibroblastvækstfaktor (FGF)-receptorer FGFR1, 2, 3 og 4, trombocytderiveret vækstfaktor (PDGF)- receptor PDGFRα, KIT og RET.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.
Lenvatinib er ikke et substrat for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2 eller BSEP.
Lenvatinib is not a substrate for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or the BSEP.
Lenvatinib kan som andre stoffer i den samme klasse påvirke sårhelingsprocessen negativt.
Lenvatinib may adversely affect the wound healing process as other agents of the same class.
Lenvatinib skal afbrydes i tilfælde af, at der udvikles en forlængelse af QT-intervallet over 500 ms.
Lenvatinib should be withheld in the event of development of QT interval prolongation greater than 500 ms.
Lenvatinib viste en minimal eller ingen hæmmende virkning på OATP1B3.
Lenvatinib showed minimal or no inhibitory effect on OATP1B3.
Lenvatinib viste minimal eller ingen hæmmende aktivitet mod P-gp-medierede og BCRP-medierede transportaktiviteter.
Lenvatinib showed minimal or no inhibitory activities toward P-gp-mediated and BCRP-mediated transport activities.
Lenvatinib-dosis bør afbrydes eller dosisjusteres efter behov afhængig af sværhedsgraden, tilstedeværelsen af EKG- ændringer og vedvarende hypocalcæmi.
Lenvatinib dose should be interrupted or dose adjusted as necessary depending on severity, presence of ECG changes, and persistence of hypocalcaemia.
Lenvatinib-eksponeringen baseret på dosisjusterede data for AUC0-t og AUC0-inf var 119 %, 107 % og 180 % af normalen for personer med hhv. let, moderat og svært nedsat leverfunktion.
Lenvatinib exposure, based on dose-adjusted AUC0-t and AUC0-inf data, was 119%, 107%, and 180% of normal for subjects with mild, moderate, and severe hepatic impairment, respectively.
Lenvatinibbehandlingen bør afbrydes eller dosis justeres efter behov, afhængig af sværhedsgraden og persistens af hypokalcæmi samt tilstedeværelse af ekg-ændringer.
Lenvatinib dose should be interrupted or dose adjusted as necessary depending on severity, presence of ECG changes, and persistence of hypocalcaemia.
LENVIMA 10 mg hårde kapsler
LENVIMA 10 mg hard capsules
LENVIMA 10 mg hårde kapsler lenvatinib
LENVIMA 10 mg hard capsules lenvatinib
LENVIMA 10 mg hårde kapsler: Hver hård kapsel indeholder 10 mg lenvatinib (som mesilat).
LENVIMA 10 mg hard capsules: - Each hard capsule contains 10 mg of lenvatinib (as mesilate).
LENVIMA 4 mg hårde kapsler lenvatinib
LENVIMA 4 mg hard capsules lenvatinib
LENVIMA 4 mg hårde kapsler LENVIMA 10 mg hårde kapsler
LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules
LENVIMA 4 mg hårde kapsler: Hver hård kapsel indeholder 4 mg lenvatinib (som mesilat).
LENVIMA 4 mg hard capsules: - Each hard capsule contains 4 mg of lenvatinib (as mesilate).
Lenvima anvendes, når kræften er skredet frem eller har bredt sig lokalt eller til andre dele af kroppen og ikke reagerer på behandling med radioaktivt jod.
Lenvima is used when the cancer has progressed or spread locally or to other parts of the body, and does not respond to treatment with radioactive iodine.
LENVIMA er indiceret til behandling af voksne patienter med progressiv, lokalt fremskreden eller metastatisk, differentieret (papillært/follikulært/Hürthle-celle) tyreoideakarcinom (DTC), refraktært over for radioaktivt jod (RAI).
LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Lenvima udleveres kun efter recept, og behandlingen skal påbegyndes og overvåges af en læge med erfaring i brug af kræftmedicin.
Lenvima can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines.
LENVIMA10 mg hårde kapsler lenvatinib
LENVIMA 10 mg hard capsules lenvatinib
Lepirudin produceres via en metode, der er kendt som ‘rekombinant DNA-teknologi’: Det fremstilles af en celle, som har modtaget et gen (DNA), der sætter den i stand til at producere lepirudin.
Lepirudin is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce lepirudin.
Lepirudin var ikke mutagent eller klastogent i standardiserede assays for sådanne effekter.
Lepirudin was not mutagenic or clastogenic in standard assays for such effects.
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR* titre ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ARL* titre ≥ 1:51
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR* titre ≥ 1:51.
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR* titre ≥ 1:51/ml
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51.
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ARL** titre ≥ 1:51
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR** titre ≥ 1:51 Inaktiveret rabiesvirus, stamme SAD Vnukovo-32 ≥ 2,0 IU***
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51 Inactivated rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU
Leptospira interrogans serogruppe Australis serovar Bratislava, stamme MSLB 1088 ALR** titre ≥ 1:51/ml
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 ALR** titre ≥ 1:51/ml
Leptospira interrogans serogruppe Canicola serovar Canicola, stamme MSLB 1090 ALR* titre ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ALR* titre ≥ 1:51/ml
Leptospira interrogans serogruppe Canicola serovar Canicola, stamme MSLB 1090 ALR* titre ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ARL* titre ≥ 1:51
Leptospira interrogans serogruppe Canicola serovar Canicola, stamme MSLB 1090 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ALR** titre ≥ 1:51
Leptospira interrogans serogruppe Canicola serovar Canicola, stamme MSLB 1090 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ARL** titre ≥ 1:51
Leptospira interrogans serogruppe Canicola serovar Canicola, stamme MSLB 1090 ALR** titre ≥ 1:51/ml
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 ALR** titre ≥ 1:51/ml
Leptospira interrogans serogruppe Icterohaemorrhagiae serovar Icterohaemorrhagiae, stamme MSLB 1089 ALR* titre ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ARL* titre ≥ 1:51
Leptospira interrogans serogruppe Icterohaemorrhagiae serovar Icterohaemorrhagiae, stamme MSLB 1089 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ALR** titre ≥ 1:51
Leptospira interrogans serogruppe Icterohaemorrhagiae serovar Icterohaemorrhagiae, stamme MSLB 1089 ALR** titre ≥ 1:51
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ARL** titre ≥ 1:51
Leptospira interrogans serogruppe Icterohaemorrhagiae serovar Icterohaemorrhagiae, stamme MSLB 1089 ALR** titre ≥ 1:51/ml
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089 ALR** titre ≥ 1:51/ml
Leptospira kirschneri serogruppe Grippotyphosa serovar Grippotyphosa, stamme MSLB 1091 ALR* titre ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR* titre ≥ 1:40/ml
Leptospira kirschneri serogruppe Grippotyphosa serovar Grippotyphosa, stamme MSLB 1091 ALR* titre ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ARL* titre ≥ 1:40
Leptospira kirschneri serogruppe Grippotyphosa serovar Grippotyphosa, stamme MSLB 1091 ALR** titre ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR** titre ≥ 1:40
Leptospira kirschneri serogruppe Grippotyphosa serovar Grippotyphosa, stamme MSLB 1091 ALR** titre ≥ 1:40
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ARL** titre ≥ 1:40
Leptospira kirschneri serogruppe Grippotyphosa serovar Grippotyphosa, stamme MSLB 1091 ALR** titre ≥ 1:40/ml
Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 ALR** titre ≥ 1:40/ml
Leptospira-vaccine
Leptospira vaccine
leptospirose, en bakteriesygdom, der kan overføres gennem inficeret urin og medføre blødning, leverbetændelse (hepatitis) og gulsot eller nyrebetændelse (nefritis) rabies (hundegalskab), en virussygdom, der kan overføres til mennesker (en zoonose) og angriber hjerne og rygmarv med døden til følge.
leptospirosis, a bacterial disease that may be transmitted via infected urine and result in bleeding, hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation); rabies, a viral zoonotic (communicable to man) disease that affects the central nervous system (brain and spinal cord), leading to death.
lereret.
well tolerated.
Les Laboratoires Servier 905 route de Saran
Les Laboratoires Servier Industrie 905 route de Saran
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, Frankrig Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co.
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co. Wicklow, Ireland
Les Laboratoires Servier Industrie, 905, route de Saran – 45520 Gidy, Frankrig Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co.
Les Laboratoires Servier Industrie, 905, route de Saran – 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co. Wicklow, Ireland
Les Laboratoires Servier Industrie, 905, route de Saran – F-45520 Gidy, Frankrig Servier (Ireland) Industries Ltd, Gorey Road – Arklow – Co.
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road – Arklow – Co. Wicklow, Ireland
Lesinurad hverken hæmmer eller inducerer CYP2C9 og 2C8 in vivo, men inducerer CYP3A i let til moderat grad.
In vivo, lesinurad is neither an inhibitor nor an inducer of CYP2C9 and 2C8, but a mild to moderate inducer of CYP3A.
Let
Mild